Template:Jilin China/Desc C.js
var content_alpha = { prospect:{ title:"Description" }, reference:[
"[1] Gonzalez-Burgos E, Gomez-Serranillos M P. Natural Products for Vulvovaginal Candidiasis Treatment: Evidence from Clinical Trials[J]. Curr Top Med Chem, 2018, 18(15): 1324-1332.", "[2] Zida A, Bamba S, Yacouba A, et al. Anti-Candida albicans natural products, sources of new antifungal drugs: A review[J]. J Mycol Med, 2017, 27(1): 1-19.", "[3] Gonzalez G M, Robledo E, Garza-Gonzalez E, et al. Efficacy of albaconazole against Candida albicans in a vaginitis model[J]. Antimicrob Agents Chemother, 2009, 53(10): 4540-1.", "[4] Andrade J T, Santos F R S, Lima W G, et al. Design, synthesis, biological activity and structure-activity relationship studies of chalcone derivatives as potential anti-Candida agents[J]. J Antibiot (Tokyo), 2018, 71(8): 702-712."
],
part: [{
title: "Inspiration",
para: [
{ type: "word", cont: "Since March, we have put forward some initial ideas including improving plant resistance, killing Lepidoptera pests, treating silicosis and treating vaginitis. In this process, a speech on women's health helped us determine our final project. The speaker mentioned some diseases that afflict women. Vaginitis, which afflicts most of women with painful treatment process, has no radical treatment method. We also found that the patients with VVC accounted for one of the largest proportions in vaginitis patients through the investigation of patients and the interview of doctors, so we finally decided to launch a project for VVC.", class: "np5" },
]
},
{
title: "Description",
para: [{
type: "word",
cont: "Goals",
class: "np2"
},
{
type: "word",
cont: "Vaginitis is a common female disease. The infection caused by (ita)C. albicans(itaed) affects 70-75% of women at least once in their lifetime(sup)[1](suped). Nowadays, the most common treatment is the use of antifungal drugs (mainly azole drugs)(sup)[2](suped). However, there are problems in the existing treatment, such as promoting the development of drug-resistance and easy relapse. Thus, developing a novel therapy approach is urgently needed. Consequently, we propose a non-antibiotic method to treat the infection caused by (ita)C. albicans(itaed) using tools of synthetic biology. It can inhibit and kill (ita)C. albicans(itaed) when it causes VVC, and activate suicide system to ensure safety when VVC is cured.",
class: "np5"
},
{
type: "word",
cont: "Advantages",
class: "np2"
},
{
type: "word",
cont: "Till now, as a commonly used antifungal drug for VVC treatment, vaginal azole preparations can inhibit the growth of (ita)C. albicans(itaed), or kill them directly(sup)[3](suped). However, the widespread usage of antifungal drugs and the increase in the number of fungal infections have led to the emergence of drug resistance, even the repeated relapse to VVC of patients(sup)[4](suped).Our project focuses on the pathogenic process of (ita)C. albicans(itaed), and is targeted to solve different virulence factors, which can slow down or even prevent the emergence of drug resistance in patients. In addition, our system can dynamically sense 4-HPA, which is specifically secreted by (ita)C. albicans(itaed), to achieve the periodic treatment of VVC and avoid relapse.",
class: "np5"
}, {
type: "word",
cont: "How?",
class: "np2"
},
{
type: "word",
cont: "We engineer a bacteria strain that includes sensing system, therapeutic system and suicide system, aiming to inhibit (ita)C. albicans(itaed). Our sensing system can sense the 4-HPA secreted by (ita)C. albicans(itaed) and activate the downstream gene expression. Different schemes are designed for different virulence factors, to reach the effect of inhibiting (ita)C. albicans(itaed). The therapeutic system consists of four parts: Bcam0581, Msp1, β-1,3-glucanase and LL-37, which can control the phase transformation of (ita)C. albicans(itaed), the formation of biofilm and other virulence factors. And considering safety, we design a suicide system that can achieve the effect that T4 holin is expressed under the condition of low (ita)C. albicans(itaed) density, leading to the death of the engineered bacteria.",
class: "np5"
},
]
}, { title: "Reference", para: [{ type: "word", cont: "[1] Gonzalez-Burgos E, Gomez-Serranillos M P. Natural Products for Vulvovaginal Candidiasis Treatment: Evidence from Clinical Trials[J]. Curr Top Med Chem, 2018, 18(15): 1324-1332.", class: "np5" }, { type: "word", cont: "[2] Zida A, Bamba S, Yacouba A, et al. Anti-Candida albicans natural products, sources of new antifungal drugs: A review[J]. J Mycol Med, 2017, 27(1): 1-19.", class: "np5" },
{ type: "word", cont: "[3] Gonzalez G M, Robledo E, Garza-Gonzalez E, et al. Efficacy of albaconazole against Candida albicans in a vaginitis model[J]. Antimicrob Agents Chemother, 2009, 53(10): 4540-1.", class: "np5" }, { type: "word", cont: "[4] Andrade J T, Santos F R S, Lima W G, et al. Design, synthesis, biological activity and structure-activity relationship studies of chalcone derivatives as potential anti-Candida agents[J]. J Antibiot (Tokyo), 2018, 71(8): 702-712.", class: "np5" },
]
},
]
}